ITM Power's Summer of Decision: From Chronos to Cromarty, Two Timelines Test the Hydrogen Thesis
04.06.2026 - 17:18:36 | boerse-global.de
ITM Power is entering a stretch where near-term regulatory verdicts and a longer-term project bet will define the trajectory of a stock that has already more than doubled this year. The company is pivoting from a pure equipment supplier to an integrated developer and operator of green hydrogen plants, a strategy that now rests on distinct milestones in June and December. The market, however, has greeted the shift with a sharp sell-off that has erased nearly a quarter of the share price in just seven trading days.
The recent turbulence stems from a classic index-rebalancing pattern. ITM Power's inclusion in the MSCI Small Cap Index at the end of May forced passive funds to buy an estimated £25 million to £30 million of stock, while short sellers simultaneously covered their positions. This push drove an intraday high of €2.58 on May 29 — a 52-week peak — before the artificial bid vanished. With no fresh corporate catalyst to fill the gap, the shares have since slid 8.3% in a single session to €1.86, leaving the stock roughly 21% below that high despite a year-to-date gain of 180%.
The June calendar is packed with make-or-break events. The most consequential is the final investment decision for the Chronos production line in Sheffield, a fully automated facility designed to churn out one gigawatt of electrolyser capacity annually from 2028 at 40% lower capital costs than current systems. The total price tag is around £120 million, with Great British Energy committing £40 million in equity and the UK energy ministry adding a £46.5 million grant. The decision hinges on clearance from the Competition and Markets Authority, also expected this month. Concurrently, the second UK hydrogen allocation round, HAR2, is nearing its first signals; on the shortlist is Uniper's Humber H2ub project, for which ITM would supply six 20-megawatt modules. Uniper's own final investment decision for the 120-megawatt Killingholme plant, which already has planning permission, is also due.
Across the country, another hydrogen venture is taking shape. ITM Power and Protium Green Solutions announced a strategic partnership on June 3 to co-develop, finance, and operate industrial green hydrogen production plants in the UK. The first concrete project is the Cromarty Hydrogen Project in the Scottish Highlands, a 15-megawatt facility that will produce around seven tonnes of green hydrogen per day — roughly 2,000 tonnes annually. Funding is already secured under the first HAR1 round, and the partners are targeting a final investment decision for December 2026. Protium will remain on the ground as lead developer, handling infrastructure, permits and power procurement, while ITM's subsidiary Hydropulse is slated as operator. The initial phase is expected to create about 30 local jobs.
Should investors sell immediately? Or is it worth buying ITM Power?
Financially, ITM's progress is visible but still loss-making. For fiscal 2026, it forecasts revenue of £40 million to £43 million, a 35% jump from the prior year, while the adjusted EBITDA loss narrowed from £16.8 million to £11.9 million. The order book stood at £152 million, with 71% classified as mature contracts. Liquidity has improved markedly following Great British Energy's equity injection: year-end cash guidance was raised to between £210 million and £215 million, up from £170 million to £175 million. A separate strategic partnership with Rheinmetall to produce synthetic fuels for NATO forces, involving hundreds of decentralised production sites across Europe, adds a military dimension to the pipeline.
Analyst opinions on the stock remain sharply divided, reflecting the binary nature of the upcoming catalysts. Morgan Stanley initiated coverage for the first time since 2021 with an Overweight rating and a target of 170 pence, conditioned on ITM securing roughly 200 megawatts of new orders and reaching EBITDA break-even by 2028. Jefferies is even more bullish at 200 pence, while Berenberg is cautious at 110 pence. UBS stands out as the sceptic with a Neutral rating and a 60-pence target. The average of twelve analysts, however, still comes out at an Outperform equivalent, with a mean price target of around £1.19.
Inside the company, sentiment is mixed. Technology director Simon Bourne sold the bulk of his 1.3 million share options at an average of 157.44 pence, citing tax obligations. In contrast, CEO Dennis Schulz has tied his own stake of the same size to the successful delivery of the Chronos electrolyser and the signing of profitable contracts — a clear alignment with the long-term thesis.
ITM Power at a turning point? This analysis reveals what investors need to know now.
The biggest overhang may be the UK government's own hydrogen strategy. While projects like Cromarty benefit from already allocated subsidy rounds, market observers report that many other initiatives have been frozen or cancelled due to a lack of reliable offtakers. Delays in updating the national hydrogen plan have deepened uncertainty. ITM and Protium's new integrated model — combining development, investment and operation — is an attempt to stabilise project execution against that backdrop.
All three June decisions will be resolved before ITM's next results day on September 15. By then, the December Cromarty FID will also be in clear view. With annualised volatility above 106%, the shares remain a vehicle where a single regulatory announcement can redraw the picture in hours — for better or worse.
Ad
ITM Power Stock: New Analysis - 4 June
Fresh ITM Power information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
